See which stocks are pulling investors into the conversation, what the crowd is saying, and whether the attention is broad or concentrated.
Top stocks by X chatter · rolling 30-day window
Azitra reportedly pauses its at-the-market equity offering and announces ex vivo results for ATR-COSF. The company's shares surged on high volume following the news, though the data is from an outside-the-body study rather than clinical trials.
Research →Prime Medicine reportedly dosed its first patient in a gene editing trial on October 5. Concurrently, data indicates a recent volume spike was not driven by short covering, with short interest remaining high at 32.8 million shares.
Research →Open any ticker to investigate the catalyst, price action, filings, earnings, news, positioning, and risks.